{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:37:30Z","timestamp":1791855450381,"version":"4.3.4"},"reference-count":148,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ejca.2021.11.001","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T09:33:33Z","timestamp":1638437613000},"page":"137-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Clinical pharmacology of cytotoxic drugs in neonates and infants: Providing evidence-based dosing guidance"],"prefix":"10.1016","volume":"164","author":[{"given":"A. Laura","family":"Nijstad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2808-5590","authenticated-orcid":false,"given":"Shelby","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arief","family":"Lalmohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inez M.","family":"B\u00e9r\u00e9nos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Parke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2395-7767","authenticated-orcid":false,"given":"Vickyanne","family":"Carruthers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2208-3970","authenticated-orcid":false,"given":"Deborah A.","family":"Tweddle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3385-1306","authenticated-orcid":false,"given":"Jordon","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michel","family":"Zwaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1939-4639","authenticated-orcid":false,"given":"Alwin D.R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1897-8678","authenticated-orcid":false,"given":"Gareth J.","family":"Veal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.11.001_bib1","first-page":"S2","article-title":"The epidemiology of infant cancers","volume":"18","author":"Birch","year":"1992","journal-title":"Br J Cancer Suppl"},{"issue":"4","key":"10.1016\/j.ejca.2021.11.001_bib2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.siny.2012.04.001","article-title":"Leukaemia & cancer in neonates","volume":"17","author":"Vormoor","year":"2012","journal-title":"Semin Fetal Neonatal Med"},{"issue":"12","key":"10.1016\/j.ejca.2021.11.001_bib3","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1200\/JCO.2016.70.3249","article-title":"Death within 1 Month of diagnosis in childhood cancer: an analysis of risk factors and scope of the problem","volume":"35","author":"Green","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2021.11.001_bib4","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/pbc.22343","article-title":"It's not easy being small","volume":"54","author":"Adamson","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2021.11.001_bib5","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00280-016-2975-0","article-title":"Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimens","volume":"77","author":"Veal","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2021.11.001_bib6","unstructured":"Steliarova-Foucher E, Colombet M, Ries L, et\u00a0al. International incidence of childhood cancer, vol. III (electronic version). Published 2017. http:\/\/iicc.iarc.fr\/results\/."},{"key":"10.1016\/j.ejca.2021.11.001_bib7","doi-asserted-by":"crossref","first-page":"101697","DOI":"10.1016\/j.canep.2020.101697","article-title":"Infant cancers in France: incidence and survival (2000\u20132014)","volume":"65","author":"Desandes","year":"2020","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"10.1016\/j.ejca.2021.11.001_bib8","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/(SICI)1097-0142(19960801)78:3<532::AID-CNCR22>3.0.CO;2-Z","article-title":"Trends in cancer incidence among children in the U.S.","volume":"78","author":"Gurney","year":"1996","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2021.11.001_bib9","doi-asserted-by":"crossref","first-page":"646","DOI":"10.3109\/08880018.2013.813099","article-title":"Cancer incidence and survival among infants in Israel, 1998\u20132007","volume":"30","author":"Rabinowicz","year":"2013","journal-title":"Pediatr Hematol Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2021.11.001_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28917","article-title":"Cancer incidence and survival trends among infants in the United States from 1975 to 2014","volume":"68","author":"Wang","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2021.11.001_bib11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/(SICI)1097-0215(19960103)65:1<34::AID-IJC7>3.0.CO;2-2","article-title":"Childhood cancer incidence in Australia, 1982\u20131991","volume":"65","author":"McWhirter","year":"1996","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2021.11.001_bib12","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/00043426-199709000-00004","article-title":"Infant Cancer in the U.S.: histology-specific incidence and trends, 1973 to 1992","volume":"19","author":"Gurney","year":"1997","journal-title":"J Pediatr Hematol Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2021.11.001_bib13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(13)70548-5","article-title":"Childhood cancer survival in Europe 1999\u20132007: results of EUROCARE-5\u2014a population-based study","volume":"15","author":"Gatta","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2021.11.001_bib14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/JCO.18.00419","article-title":"Defining risk factors for chemotherapeutic intervention in infants with stage 4S neuroblastoma: a report from children's oncology group study ANBL0531","volume":"37","author":"Twist","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2021.11.001_bib15","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0887-8994(02)00472-1","article-title":"Perinatal brain tumors: a review of 250 cases","volume":"27","author":"Isaacs","year":"2002","journal-title":"Pediatr Neurol"},{"issue":"S11","key":"10.1016\/j.ejca.2021.11.001_bib16","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1002\/cncr.21249","article-title":"Long-term outcomes of adult survivors of childhood cancer","volume":"104","author":"Robison","year":"2005","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2021.11.001_bib17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11136-005-0198-7","article-title":"Health status in survivors of cancer in childhood and adolescence","volume":"15","author":"Pogany","year":"2006","journal-title":"Qual Life Res"},{"issue":"8","key":"10.1016\/j.ejca.2021.11.001_bib18","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/jnci\/93.8.618","article-title":"Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study","volume":"93","author":"Neglia","year":"2001","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.ejca.2021.11.001_bib19","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/cncr.11117","article-title":"Utilization of special education services and educational attainment among long-term survivors of childhood cancer","volume":"97","author":"Mitby","year":"2003","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2021.11.001_bib20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.siny.2012.05.002","article-title":"Neonatal neuroblastoma","volume":"17","author":"Fisher","year":"2012","journal-title":"Semin Fetal Neonatal Med"},{"issue":"5","key":"10.1016\/j.ejca.2021.11.001_bib21","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/(SICI)1097-0142(19970901)80:5<834::AID-CNCR2>3.0.CO;2-L","article-title":"Neuroblastoma 4S: a heterogeneous disease with variable risk factors and treatment strategies","volume":"80","author":"van Noesel","year":"1997","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2021.11.001_bib22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood-2018-04-785980","article-title":"How I treat infant leukemia","volume":"133","author":"Brown","year":"2019","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.ejca.2021.11.001_bib23","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.19.00261","article-title":"Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the interfant-06 protocol: results from an international phase III randomized study","volume":"37","author":"Pieters","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.11.001_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2015.00037","article-title":"Acute myeloid leukemia in infants: biology and treatment","volume":"3","author":"Masetti","year":"2015","journal-title":"Front Pediatr"},{"key":"10.1016\/j.ejca.2021.11.001_bib25","doi-asserted-by":"crossref","first-page":"101669","DOI":"10.1016\/j.canep.2020.101669","article-title":"Early deaths from childhood cancer in Germany 1980-2016","volume":"65","author":"Becker","year":"2020","journal-title":"Cancer Epidemiol"},{"issue":"6","key":"10.1016\/j.ejca.2021.11.001_bib26","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00431-004-1425-x","article-title":"Early deaths from childhood cancer","volume":"163","author":"Pastore","year":"2004","journal-title":"Eur J Pediatr"},{"issue":"5","key":"10.1016\/j.ejca.2021.11.001_bib27","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/(SICI)1096-911X(200005)34:5<343::AID-MPO5>3.0.CO;2-B","article-title":"Early deaths in childhood cancer","volume":"34","author":"Hamre","year":"2000","journal-title":"Med Pediatr Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2021.11.001_bib28","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1365-2141.2010.08389.x","article-title":"Early and treatment-related deaths in childhood acute myeloid leukaemia in the Nordic countries: 1984-2003","volume":"151","author":"Molgaard-Hansen","year":"2010","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.ejca.2021.11.001_bib29","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1182\/blood-2005-07-3011","article-title":"Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group","volume":"108","author":"Hilden","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejca.2021.11.001_bib30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1200\/JCO.1988.6.1.51","article-title":"Chemotherapy-related toxicity in infants treated according to the second national Wilms' tumor study","volume":"6","author":"Morgan","year":"1988","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2021.11.001_bib31","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0022-3476(81)80785-8","article-title":"Life-threatening neuropathy and hepatotoxicity in infants during induction therapy for acute lymphoblastic leukemia","volume":"98","author":"Woods","year":"1981","journal-title":"J Pediatr"},{"issue":"11","key":"10.1016\/j.ejca.2021.11.001_bib32","doi-asserted-by":"crossref","first-page":"26636","DOI":"10.1002\/pbc.26636","article-title":"Dosing anticancer drugs in infants: current approach and recommendations from the children's oncology Group's chemotherapy Standardization task force","volume":"64","author":"Balis","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2021.11.001_bib33","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.siny.2012.03.002","article-title":"Chemotherapy in newborns and preterm babies","volume":"17","author":"Veal","year":"2012","journal-title":"Semin Fetal Neonatal Med"},{"issue":"4","key":"10.1016\/j.ejca.2021.11.001_bib34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/00003088-198814040-00001","article-title":"Principles of drug biodisposition in the neonate","volume":"14","author":"Besunder","year":"1988","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"10.1016\/j.ejca.2021.11.001_bib35","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology-drug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","year":"2003","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ejca.2021.11.001_bib36","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2165\/00003088-200645110-00003","article-title":"Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations","volume":"45","author":"Bartelink","year":"2006","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.ejca.2021.11.001_bib37","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2125.2009.03591.x","article-title":"What is the right dose for children?","volume":"70","author":"Cella","year":"2010","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.ejca.2021.11.001_bib38","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1158\/1078-0432.CCR-12-2225","article-title":"Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma","volume":"19","author":"Veal","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ejca.2021.11.001_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13081868","article-title":"Pharmacokinetics and safety of a novel oral liquid formulation of 13-cis retinoic acid in children with neuroblastoma: a randomized crossover clinical trial","volume":"13","author":"Veal","year":"2021","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.ejca.2021.11.001_bib40","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1158\/1078-0432.CCR-19-2685","article-title":"Exposure\u2013toxicity association of cyclophosphamide and its metabolites in infants and young children with primary brain tumors: implications for dosing","volume":"26","author":"Campagne","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2021.11.001_bib41","first-page":"14","article-title":"Pharmacokinetics and pharmacogenetics of cyclophosphamide in a neonate and infant childhood cancer patient population","author":"Barnett","year":"2021","journal-title":"Pharm Times"},{"issue":"10","key":"10.1016\/j.ejca.2021.11.001_bib42","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.bbmt.2017.06.021","article-title":"Pharmacokinetics and model-based dosing to optimize fludarabine therapy in pediatric hematopoietic cell transplant recipients","volume":"23","author":"Ivaturi","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.ejca.2021.11.001_bib43","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41409-018-0260-z","article-title":"Pharmacokinetics of fludarabine and its association with clinical outcomes in paediatric haematopoietic stem cell transplantation patients","volume":"54","author":"Chung","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.ejca.2021.11.001_bib44","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s40262-018-0715-9","article-title":"Population pharmacokinetics of fludarabine in children and adults during conditioning prior to allogeneic hematopoietic cell transplantation","volume":"58","author":"Langenhorst","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ejca.2021.11.001_bib45","article-title":"Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients","author":"Barnett","year":"2021","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2021.11.001_bib46","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s40262-014-0153-2","article-title":"Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer","volume":"53","author":"Hill","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ejca.2021.11.001_bib47","series-title":"Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: children's Oncology Group Study ADVL06B1","author":"Skolnik","year":"2021"},{"issue":"36","key":"10.1016\/j.ejca.2021.11.001_bib48","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2021.11.001_bib49","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40262-019-00823-8","article-title":"Population pharmacokinetics of blinatumomab in pediatric and adult patients with hematological malignancies","volume":"59","author":"Clements","year":"2020","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.ejca.2021.11.001_bib50","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s00280-014-2575-9","article-title":"Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma","volume":"74","author":"Desai","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2021.11.001_bib51","first-page":"S23","article-title":"Disposition of antineoplastic agents in the very young child","volume":"18","author":"McLeod","year":"1992","journal-title":"Br J Cancer Suppl"},{"issue":"11","key":"10.1016\/j.ejca.2021.11.001_bib52","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s40262-015-0272-4","article-title":"Age-dependent pharmacokinetics of doxorubicin in children with cancer","volume":"54","author":"V\u00f6ller","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.ejca.2021.11.001_bib53","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00280-016-3174-8","article-title":"Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a \u201cEuropean Pediatric Oncology Off-patents Medicines Consortium\u201d trial","volume":"78","author":"Krischke","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.ejca.2021.11.001_bib54","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00280-017-3309-6","article-title":"Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?","volume":"80","author":"Kunarajah","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.ejca.2021.11.001_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40360-020-00417-2","article-title":"Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedure","volume":"21","author":"Siebel","year":"2020","journal-title":"BMC Pharmacol Toxicol"},{"issue":"2","key":"10.1016\/j.ejca.2021.11.001_bib56","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/pbc.20089","article-title":"A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group Study (Now the Children's Oncology Group)","volume":"43","author":"Bell","year":"2004","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2021.11.001_bib57","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/CAD.0b013e32831bc086","article-title":"Thioguanine pharmacokinetics in induction therapy of children with acute myeloid leukemia","volume":"20","author":"Palle","year":"2009","journal-title":"Anti Cancer Drugs"},{"issue":"6","key":"10.1016\/j.ejca.2021.11.001_bib58","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","article-title":"A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study","volume":"99","author":"Avramis","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejca.2021.11.001_bib59","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-2141.2009.07923.x","article-title":"A population pharmacokinetic model for pegylated-asparaginase in children","volume":"148","author":"Hempel","year":"2010","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.ejca.2021.11.001_bib60","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1080\/10428194.2018.1538507","article-title":"Asparaginase treatment in infants with acute lymphoblastic leukemia; pharmacokinetics and asparaginase hypersensitivity in interfant-06","volume":"60","author":"Albertsen","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejca.2021.11.001_bib61","first-page":"242289","article-title":"Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic model","author":"Kloos","year":"2019","journal-title":"Haematologica"},{"issue":"22","key":"10.1016\/j.ejca.2021.11.001_bib62","doi-asserted-by":"crossref","first-page":"6703","DOI":"10.1158\/1078-0432.CCR-07-1376","article-title":"Population pharmacokinetic analysis of topotecan in pediatric cancer patients","volume":"13","author":"Schaiquevich","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ejca.2021.11.001_bib63","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1124\/dmd.115.068676","article-title":"Population pharmacokinetics of oral topotecan in infants and very young children with brain tumors demonstrates a role of ABCG2 rs4148157 on the absorption rate constant","volume":"44","author":"Roberts","year":"2016","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.ejca.2021.11.001_bib64","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1200\/JCO.1989.7.1.100","article-title":"A pharmacokinetic study of high-dose continuous\u00a0infusion cisplatin in children with solid tumors","volume":"7","author":"Dominici","year":"1989","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2021.11.001_bib65","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/S0959-8049(97)00341-9","article-title":"Cisplatin pharmacokinetics in children with cancer","volume":"33","author":"Peng","year":"1997","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2021.11.001_bib66","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00280-018-3625-5","article-title":"Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report","volume":"82","author":"Thomas","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1\u20132","key":"10.1016\/j.ejca.2021.11.001_bib67","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s002800050536","article-title":"NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias","volume":"39","author":"Periclou","year":"1996","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1\u20132","key":"10.1016\/j.ejca.2021.11.001_bib68","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jchromb.2007.11.033","article-title":"Simultaneous quantitation of dexamethasone palmitate and dexamethasone in human plasma by liquid chromatography\/tandem mass spectrometry","volume":"862","author":"Yang","year":"2008","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"issue":"7","key":"10.1016\/j.ejca.2021.11.001_bib69","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood-2011-09-381731","article-title":"Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia","volume":"119","author":"Kawedia","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2021.11.001_bib70","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.17572","article-title":"Evaluation of the pharmacokinetics of prednisolone in paediatric patients with acute lymphoblastic leukaemia treated according to Dutch Childhood Oncology Group protocols and its relation to treatment response","author":"Sassen","year":"2021","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.ejca.2021.11.001_bib71","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1177\/0091270004267595","article-title":"Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia","volume":"44","author":"Buckwalter","year":"2004","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.ejca.2021.11.001_bib72","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40262-018-0694-x","article-title":"Population pharmacokinetics of gemtuzumab ozogamicin in pediatric patients with relapsed or refractory acute myeloid leukemia","volume":"58","author":"Masters","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"20","key":"10.1016\/j.ejca.2021.11.001_bib73","first-page":"6525","article-title":"Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report","volume":"50","author":"Reid","year":"1990","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.ejca.2021.11.001_bib74","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2165\/00003088-200140080-00005","article-title":"Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease","volume":"40","author":"Kerbusch","year":"2001","journal-title":"Clin Pharmacokinet"},{"issue":"16","key":"10.1016\/j.ejca.2021.11.001_bib75","first-page":"3758","article-title":"Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children","volume":"53","author":"Boddy","year":"1993","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2021.11.001_bib76","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s00280-008-0692-z","article-title":"Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group","volume":"62","author":"Thompson","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.ejca.2021.11.001_bib77","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/BF00257235","article-title":"Pharmacokinetics of low-dose methotrexate in children receiving maintenance therapy for acute lymphoblastic leukaemia","volume":"10","author":"Pinkerton","year":"1982","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.ejca.2021.11.001_bib78","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/BF00570494","article-title":"Pharmacokinetics of oral and intramuscular methotrexate in children with acute lymphoblastic leukaemia","volume":"20","author":"Pearson","year":"1987","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5\u20136","key":"10.1016\/j.ejca.2021.11.001_bib79","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/mpo.2950170520","article-title":"Disposition of oral methotrexate in children with acute lymphoblastic leukemia and its relation to 6-mercaptopurine pharmacokinetics","volume":"17","author":"Koren","year":"1989","journal-title":"Med Pediatr Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2021.11.001_bib80","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1182\/blood.V92.10.3569","article-title":"Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint Children's Cancer Group and Pediatric Oncology Branch study","volume":"92","author":"Balis","year":"1998","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ejca.2021.11.001_bib81","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00280-003-0670-4","article-title":"Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors","volume":"52","author":"Panetta","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.ejca.2021.11.001_bib82","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00280-003-0677-x","article-title":"Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients","volume":"52","author":"Riccardi","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.ejca.2021.11.001_bib83","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00280-009-1015-8","article-title":"Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors","volume":"65","author":"Meany","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.ejca.2021.11.001_bib84","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/pbc.22999","article-title":"High dose methotrexate treatment in children with acute lymphoblastic leukaemia may be optimised by a weight-based dose calculation","volume":"57","author":"J\u00f6nsson","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2021.11.001_bib85","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s40262-018-00734-0","article-title":"The population pharmacokinetics of high-dose methotrexate in infants with acute lymphoblastic leukemia highlight the need for bedside individualized dose adjustment: a report from the children's oncology group","volume":"58","author":"Beechinor","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.ejca.2021.11.001_bib86","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00280-019-03977-1","article-title":"Population pharmacokinetics of methotrexate in Mexican pediatric patients with acute lymphoblastic leukemia","volume":"85","author":"Medellin-Garibay","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.ejca.2021.11.001_bib87","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/jcph.1349","article-title":"Population pharmacokinetic study and individual dose adjustments of high-dose methotrexate in Chinese pediatric patients with acute lymphoblastic leukemia or osteosarcoma","volume":"59","author":"Hui","year":"2019","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.ejca.2021.11.001_bib88","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/bdd.2221","article-title":"Population pharmacokinetics of high-dose methotrexate in Chinese pediatric patients with medulloblastoma","volume":"41","author":"yuan","year":"2020","journal-title":"Biopharm Drug Dispos"},{"issue":"1","key":"10.1016\/j.ejca.2021.11.001_bib89","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/cts.12879","article-title":"Effect of SLCO1B1 polymorphisms on high-dose methotrexate clearance in children and young adults with leukemia and lymphoblastic lymphoma","volume":"14","author":"Schulte","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.ejca.2021.11.001_bib90","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.701452","article-title":"Population pharmacokinetics of high-dose methotrexate in Chinese pediatric patients with acute lymphoblastic leukemia","volume":"12","author":"Gao","year":"2021","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.ejca.2021.11.001_bib91","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.2165\/00003088-200645120-00007","article-title":"Population pharmacokinetics of high-dose methotrexate in\u00a0children\u00a0with acute lymphoblastic leukaemia","volume":"45","author":"Aumente","year":"2006","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.ejca.2021.11.001_bib92","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00280-014-2614-6","article-title":"Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections","volume":"75","author":"Wright","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.ejca.2021.11.001_bib93","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00280-019-03966-4","article-title":"Population pharmacokinetic analysis of high-dose methotrexate in pediatric and adult oncology patients","volume":"84","author":"Kawakatsu","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.ejca.2021.11.001_bib94","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/bcp.14160","article-title":"Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumours","volume":"86","author":"Panetta","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.ejca.2021.11.001_bib95","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/sj.leu.2401673","article-title":"Individualised methotrexate dosing in children with relapsed acute lymphoblastic leukemia","volume":"14","author":"Wall","year":"2000","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.ejca.2021.11.001_bib96","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00280-006-0394-3","article-title":"A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia","volume":"60","author":"Piard","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"10.1016\/j.ejca.2021.11.001_bib97","first-page":"769","article-title":"High-dose methotrexate in children with acute lymphoblastic leukemia: 7-hydroxymethotrexate systemic exposure and urinary concentrations at the steady state correlate well with those of methotrexate","volume":"60","author":"Chl\u00e1dkov\u00e1","year":"2010","journal-title":"Arzneimittelforschung"},{"issue":"2","key":"10.1016\/j.ejca.2021.11.001_bib98","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-2710.2010.01179.x","article-title":"Methotrexate pharmacokinetics in childhood acute lymphoblastic leukaemia: a prognostic value","volume":"36","author":"Martelli","year":"2011","journal-title":"J Clin Pharm Ther"},{"issue":"9","key":"10.1016\/j.ejca.2021.11.001_bib99","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046015","article-title":"Population PK\/PD model of homocysteine concentrations after high-dose methotrexate treatment in patients with acute lymphoblastic leukemia","volume":"7","author":"R\u00fchs","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ejca.2021.11.001_bib100","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/sj.leu.2402455","article-title":"Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia","volume":"16","author":"Lacayo","year":"2002","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.ejca.2021.11.001_bib101","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1200\/JCO.2000.18.21.3614","article-title":"Prospective validation of renal function\u2013based carboplatin dosing in children with cancer: a United Kingdom children's cancer study group trial","volume":"18","author":"Thomas","year":"2000","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2021.11.001_bib102","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1200\/JCO.1993.11.12.2314","article-title":"Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group","volume":"11","author":"Newell","year":"1993","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2021.11.001_bib103","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1200\/JCO.1992.10.4.520","article-title":"Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer","volume":"10","author":"Jodrell","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.11.001_bib104","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0305-7372(85)90018-0","article-title":"Phase I studies with carboplatin at the Royal Marsden hospital","volume":"12","author":"Calvert","year":"1985","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"10.1016\/j.ejca.2021.11.001_bib105","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2021.11.001_bib106","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/bcp.14419","article-title":"Over a decade of experience with carboplatin therapeutic drug monitoring in a childhood cancer setting in the United Kingdom","volume":"87","author":"Barnett","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.ejca.2021.11.001_bib107","doi-asserted-by":"crossref","first-page":"27672","DOI":"10.1002\/pbc.27672","article-title":"Fundamental problems with pediatric adaptive dosing of carboplatin using nuclear-medicine-based estimates of renal function","volume":"66","author":"Adamson","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ejca.2021.11.001_bib108","doi-asserted-by":"crossref","unstructured":"Allen S, Wilson MW, Watkins A, et\u00a0al. Comparison of two methods for carboplatin dosing in children with retinoblastoma. Pediatr Blood Cancer. Published online 2010. https:\/\/doi.org\/10.1002\/pbc.22467.","DOI":"10.1002\/pbc.22467"},{"issue":"10","key":"10.1016\/j.ejca.2021.11.001_bib109","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1200\/JCO.2011.36.9744","article-title":"Carboplatin-associated ototoxicity in children with retinoblastoma","volume":"30","author":"Qaddoumi","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2021.11.001_bib110","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1200\/JCO.2011.39.4254","article-title":"A cautionary tale: dosing chemotherapy in infants with retinoblastoma","volume":"30","author":"Leahey","year":"2012","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.ejca.2021.11.001_bib111","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/j.ejca.2015.07.011","article-title":"Carboplatin therapeutic monitoring in preterm and full-term neonates","volume":"51","author":"Veal","year":"2015","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2021.11.001_bib112","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.drudis.2014.04.005","article-title":"Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics","volume":"19","author":"Ten Brink","year":"2014","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/j.ejca.2021.11.001_bib113","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2125.2008.03166.x","article-title":"Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients","volume":"66","author":"Nath","year":"2008","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.ejca.2021.11.001_bib114","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bbmt.2008.11.022","article-title":"Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation","volume":"15","author":"Bartelink","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.ejca.2021.11.001_bib115","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bbmt.2013.11.027","article-title":"Fludarabine and exposure-targeted busulfan compares favorably with busulfan\/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity","volume":"20","author":"Bartelink","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.ejca.2021.11.001_bib116","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1016\/S2352-3026(16)30114-4","article-title":"Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis","volume":"3","author":"Bartelink","year":"2016","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.ejca.2021.11.001_bib117","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/bmt.2015.218","article-title":"Should busulfan therapeutic range be narrowed in pediatrics? Experience from a large cohort of hematopoietic stem cell transplant children","volume":"51","author":"Philippe","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.ejca.2021.11.001_bib118","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/sj.bmt.1704209","article-title":"Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results","volume":"32","author":"Dalle","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.ejca.2021.11.001_bib119","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.bbmt.2006.10.026","article-title":"Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Schechter","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.ejca.2021.11.001_bib120","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1399-3046.2008.01098.x","article-title":"Evaluating pharmacokinetics and pharmacodynamics of intravenous busulfan in pediatric patients receiving bone marrow transplantation","volume":"13","author":"Kim","year":"2009","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.ejca.2021.11.001_bib121","doi-asserted-by":"crossref","unstructured":"Wall DA, Chan KW, Nieder ML, et\u00a0al. Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation. Pediatr Blood Cancer. Published online 2009. https:\/\/doi.org\/10.1002\/pbc.22227.","DOI":"10.1002\/pbc.22227"},{"issue":"5","key":"10.1016\/j.ejca.2021.11.001_bib122","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/11598180-000000000-00000","article-title":"Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing","volume":"51","author":"Bartelink","year":"2012","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.ejca.2021.11.001_bib123","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/FTD.0b013e31824c2f60","article-title":"Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation","volume":"34","author":"Paci","year":"2012","journal-title":"Ther Drug Monit"},{"issue":"11","key":"10.1016\/j.ejca.2021.11.001_bib124","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.bbmt.2013.08.014","article-title":"Effect of weight and\u00a0maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation","volume":"19","author":"Savic","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.ejca.2021.11.001_bib125","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1158\/1078-0432.CCR-13-1960","article-title":"Busulfan in infant to adult hematopoietic cell\u00a0transplant recipients: a population pharmacokinetic model for initial and bayesian dose personalization","volume":"20","author":"McCune","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2021.11.001_bib126","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/FTD.0000000000000276","article-title":"Accurately achieving target busulfan exposure in children and adolescents with very limited sampling and the BestDose software","volume":"38","author":"Neely","year":"2016","journal-title":"Ther Drug Monit"},{"issue":"24","key":"10.1016\/j.ejca.2021.11.001_bib127","first-page":"5509","article-title":"Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan","volume":"57","author":"Gibbs","year":"1997","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.ejca.2021.11.001_bib128","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/S0090-9556(24)14957-4","article-title":"Up-regulation of glutathione S-transferase activity in enterocytes of young children","volume":"27","author":"Gibbs","year":"1999","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.ejca.2021.11.001_bib129","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/bcp.13566","article-title":"Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation","volume":"84","author":"Nava","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"14","key":"10.1016\/j.ejca.2021.11.001_bib130","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.2217\/pgs.15.98","article-title":"Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"16","author":"Choi","year":"2015","journal-title":"Pharmacogenomics"},{"issue":"7","key":"10.1016\/j.ejca.2021.11.001_bib131","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/bmt.2012.265","article-title":"Glutathione S-transferase gene variations influence BU pharmacokinetics and outcome of hematopoietic SCT in pediatric patients","volume":"48","author":"Ansari","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"53","key":"10.1016\/j.ejca.2021.11.001_bib132","doi-asserted-by":"crossref","first-page":"90852","DOI":"10.18632\/oncotarget.20310","article-title":"GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study","volume":"8","author":"Ansari","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.ejca.2021.11.001_bib133","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/FTD.0b013e3181817428","article-title":"Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients","volume":"30","author":"Zwaveling","year":"2008","journal-title":"Ther Drug Monit"},{"issue":"10","key":"10.1016\/j.ejca.2021.11.001_bib134","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1177\/0091270010382915","article-title":"Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients","volume":"51","author":"Abbasi","year":"2011","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.ejca.2021.11.001_bib135","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1177\/0091270008321940","article-title":"Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation","volume":"48","author":"Johnson","year":"2008","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.ejca.2021.11.001_bib136","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/sj.bmt.1704446","article-title":"Busulfan in pediatrics: a novel dosing to improve safety\/efficacy for hematopoietic progenitor cell transplantation recipients","volume":"33","author":"Nguyen","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.ejca.2021.11.001_bib137","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/jcph.1089","article-title":"Multistep unified models using prior knowledge for the prediction of drug clearance in neonates and infants","volume":"58","author":"Tegenge","year":"2018","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.ejca.2021.11.001_bib138","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/FTD.0000000000000131","article-title":"Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use","volume":"37","author":"Long-Boyle","year":"2015","journal-title":"Ther Drug Monit"},{"issue":"7","key":"10.1016\/j.ejca.2021.11.001_bib139","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00228-014-1692-z","article-title":"Population pharmacokinetics of intravenous busulfan in children: revised body weight-dependent NONMEM\u00ae model to optimize dosing","volume":"70","author":"Diestelhorst","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.ejca.2021.11.001_bib140","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/pbc.22959","article-title":"Weight-based strategy of dose administration in children using intravenous\u00a0busulfan: clinical and pharmacokinetic results","volume":"58","author":"Michel","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ejca.2021.11.001_bib141","unstructured":"Pierre Fabre M\u00e9dicament. Summary of product characteristics Busilvex. Published 2008. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/busilvex-epar-product-information_en.pdf. [Accessed 7 August 2020]."},{"issue":"1","key":"10.1016\/j.ejca.2021.11.001_bib142","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/bmt.2012.105","article-title":"The pharmacokinetics and safety of twice daily i.v. BU during conditioning in pediatric allo-SCT recipients","volume":"48","author":"Le Gall","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ejca.2021.11.001_bib143","unstructured":"European Commission. Ethical considerations for clinical trials on medicinal products with the paediatric population. Recommendations of the Ad hoc group for the development of implementing guidelines for Directive 2001\/20\/EC relating to good clinical practice in the conduct. Published online 2008."},{"issue":"4","key":"10.1016\/j.ejca.2021.11.001_bib144","doi-asserted-by":"crossref","first-page":"350","DOI":"10.2174\/1574884709666140520153308","article-title":"Pharmacokinetic studies in infants using minimal-risk study designs","volume":"9","author":"Autmizguine","year":"2014","journal-title":"Curr Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.ejca.2021.11.001_bib145","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s40262-015-0291-1","article-title":"Pharmacokinetic studies in neonates: the utility of an opportunistic sampling design","volume":"54","author":"Leroux","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"10.1016\/j.ejca.2021.11.001_bib146","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1124\/dmd.115.068031","article-title":"Physiologically based pharmacokinetic modeling in pediatric oncology drug development","volume":"44","author":"Rioux","year":"2016","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.ejca.2021.11.001_bib147","first-page":"695","article-title":"Pharmacokinetic studies in children: recommendations for practice and research","volume":"103","author":"Barker","year":"2018","journal-title":"Arch Dis Child"},{"issue":"4","key":"10.1016\/j.ejca.2021.11.001_bib148","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pbc.28132","article-title":"Pharmacokinetics and population pharmacokinetics in pediatric oncology","volume":"67","author":"Sassen","year":"2020","journal-title":"Pediatr Blood Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921012016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921012016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:35:42Z","timestamp":1760733342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921012016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":148,"alternative-id":["S0959804921012016"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.11.001","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical pharmacology of cytotoxic drugs in neonates and infants: Providing evidence-based dosing guidance","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.09.014","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}